Biogen, which has big RTP presence, is laying off 11% of its workforce
Drug giant Biogen is laying off some 1,000 employees – or 11% of its workforce – with the first cuts being disclosed in Cambridge, Mass. where the company is based.
Read More
biogen
Biogen to expand rare disease treatment efforts with $7B-plus acquisition
The Alzheimer’s treatment developer which has a significant presence in Research Triangle Park says it will pay $172.50 in cash for each share of Texas-based Reata in a deal it expects to close by the end of this year.
Read More
FDA approves first drug to target a genetic cause of ALS – it’s from Biogen
The U.S Food and Drug Administration approved Biogen’s ALS drug QALSODY Tuesday afternoon.
Read More
FDA could fully approve Alzheimer’s drug from partners Eisai & Biogen by July 6
Japan-based pharma Eisai and its US partner Biogen, which has a large campus in RTP, could receive full FDA approval for their Alzheimer’s drug by July 6, the companies announced Monday.
Read More
Earnings reports: Syneos, Biogen, Martin Marietta, Albemarle, Sonic Automotive, Investors Title
Earnings reports are out for numerous North Carolina firms as well as Biogen which has a large campus in RTP. Here’s a roundup.
Read More
New Alzheimer’s drug is off to a slow start – here are the reasons why from cost to coverage
The first drug to show that it slows Alzheimer’s is on sale, but treatment for most patients is still several months away. Here’s what is happening.
Read More
Alzheimer’s drug from Biogen, partner receives FDA approval
U.S. health officials on Friday approved a closely watched Alzheimer’s drug that modestly slows the brain-robbing disease, albeit with potential safety risks that patients and their doctors will have to carefully weigh.
Read More
Biogen’s expensive Alzheimer’s drug OK process was ‘rife with irregularities,’ congressional probe finds
A congressional investigation found that the US Food and Drug Administration’s “atypical collaboration” to approve a high-priced Alzheimer’s drug from Biogen was “rife with irregularities.”
Read More
New drug from Biogen, Eisai slows Alzheimer’s – but will it make a difference?
An experimental Alzheimer’s drug from Biogen and partner Eisai modestly slowed the brain disease’s inevitable worsening, researchers report – but it remains unclear how much difference that might make in people’s lives.
Read More
